Compare Incyte Corporation (INCY) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs S&P Global Inc — how do they compare? Incyte Corporation trades at $120.5 (market cap $24.54B), while S&P Global Inc trades at $406.47 (market cap $120.48B). The key difference: S&P Global Inc is far larger — about 4.9× Incyte Corporation's market cap, and S&P Global Inc pays a 0.95% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SPGI | |
|---|---|---|
Market Cap | $24.54B | $120.48B |
Sector | Health | Financials |
52-Week High | $129.93 | $534.79 |
52-Week Low | $81.61 | $370.42 |
Enterprise Value | $20.04B | $131.97B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
S&P Global (SPGI) trades at $410.94, up 0.67% on the day, with a bearish technical signal despite strong fundamentals. Revenue grew to $15.34B in 2025, with a net income margin of 30.54%, while analyst consensus remains overwhelmingly bullish with a $523.20 price target. Recent news highlights AI integration with Microsoft and strong Q2 2026 earnings beats.
The outlook is positive given robust profitability and strategic expansions, but risks include technical weakness and debt levels. Upside potential exists if the stock rebounds toward analyst targets, though investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
